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INTRODUCTION
Worldwide, gastric cancer incidence ranks second among men 
and third among women, and the cancer is the second leading 
cause of cancer-related deaths.1-3 Despite greater understand-
ing of genetic and epigenetic various cancer events, the ab-
sence of biomarkers for identification of gastric cancer has re-
mained a problem.4 Also, among various anti-cancer therapies 
for gastric cancer, chemotherapy, which is the most common 
therapy, shows limited efficacy.5 Therefore, identifying prog-
nosis marker and targeted therapy for gastric cancer may im-
prove the survival of advanced gastric cancer patients.6 Although 
many studies have suggested the involvement of various molec-
ular signaling pathways in gastric tumorigenesis and related 
prognostic markers or therapeutic targets, the actual molecular 
mechanisms thereof have not been fully elucidated.7,8 There-
fore, reliable and feasible prognostic markers or therapeutic 
targets for gastric cancer remain an unmet need.
Heat shock factor 1 (HSF1) is a key transcription factor that 
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initiates the expression of heat shock proteins (HSPs) by bind-
ing to consensus motifs, such as heat shock elements and oth-
er genes, in response to cellular stress, thereby allowing the cell 
to adapt and prolong survival. HSPs, such as HSP27, HSP70, 
and HSP90, are important chaperone proteins that promote 
proper folding, transportation, and degradation of proteins 
within cells.9-12 HSF1 activation is repressed by interaction with 
overexpressed HSP in non-tumor cells.9-13 However, this feed-
back inhibition may be ineffective in tumor cells. Several stud-
ies have linked increased HSF1 activity to malignant cell 
growth.9 This pro-malignant activity is induced upon the bind-
ing of HSF1 to the promoters and the subsequent initiation of 
the expression of certain genes independent of heat shock.11,14 
Several studies have demonstrated that HSF1 is overexpressed 
in solid tumor cancers, including esophageal squamous cell, 
breast, hepatocellular, osteosarcoma, non-small cell lung, and 
pancreatic cancer.15-18 Furthermore, evidence implies that the 
elevated expression of HSF1 is correlated with poor survival in 
patients with cancer.18 We prepared HSF1-expressing gastric 
cancer cells and studied their proliferation and motility and 
evaluated HSF1 expression. The same experiments were ex-
tended in tissues from patients with gastric cancer to deter-
mine the clinical significance of HSF1 expression in gastric 
cancer.
MATERIALS AND METHODS
Cell culture
The human gastric cancer cell lines AGS and MKN28 were 
obtained from the Korean Cell Line Bank (Seoul, Korea) and 
cultured in Roswell Park Memorial Institute (RPMI)-1640 me-
dium supplemented with 10% fetal bovine serum (FBS) and 
1% antibiotics (Invitrogen, Thermo Fisher Scientific, Waltham, 
MA, USA) at 37°C in a humidified incubator with a 5% CO2 at-
mosphere.
Cell proliferation assay
AGS and MKN28 cells were plated in 96-well plates (3×103 
cells/well). After incubation for 24 hours, the cells were trans-
fected with siRNA (scRNA or HSF1 siRNA) and vector plasmid 
(pcDNA_EV or pcDNA_HSF1). WST-1 solution (Daeil Lab Ser-
vices Co., Ltd, Seoul, Korea) was added to each well 48 hours 
after transfection. The plates were incubated for another 1–2 
hours and gently shaken. Absorbance was then measured at a 
wavelength of 450 nm.
Transwell migration and invasion assays 
AGS and MKN28 cells were transfected with siRNA (scRNA or 
HSF1 siRNA) and vector plasmid (pcDNA_EV or pcDNA_
HSF1). After 24-hour transfection, 1×104 cells from each well 
were isolated and added to the upper transwell chamber (Corn-
ing Costar, Tewksbury, MA, USA) that carried a filter coated 
with 0.5 mg/mL of collagen type I (BD Biosciences, Seoul, Ko-
rea) for the migration assay or a filter coated with Matrigel (1:15) 
(BD Biosciences) for the invasion assay. RPMI-1640 containing 
10% FBS and 1% antibiotics was added to the lower chamber, 
and the plates were incubated for 20 hours. Cells that migrated 
and invaded were quantified after hematoxylin and eosin stain-
ing, as previously described.18 For quantification, cells were 
counted in five randomly selected areas of each well using 
wide-field microscopy. Data are expressed as mean±SEM from 
three independent experiments.
Transfection of siRNA and HSF1 construction 
Transfection of human HSF1 siRNAs or scRNA was performed 
using Lipofectamine RNAiMAX reagent (Invitrogen) according 
to the manufacturer’s protocol. The coding strands of HSF1 
siRNAs purchased from Genolution Inc. (Seoul, Korea) were 
as follows: 1) 5'-GAACGACAGUGGCUCAGCAUU-3' and 2) 
5'-CCACUUGGAUGCUAUGGACUU-3'. Human HSF1 was 
cloned into the pcDNA-3.0-Flag plasmid between EcoR1 and 
Xho1 restriction enzyme sites to obtain the pcDNA_HSF1 con-
struct. The full-length HSF1 cDNA was amplified with poly-
merase chain reaction (PCR) using the primers 5'-GAATTCA 
TGGATCTGCCCGTGGGCCC-3' (sense) and 5'-CTCGAG 
CTAGGAGACAGTGGGGTCCT-3' (antisense). The clone for 
HSF1 cDNA was provided by the Korea Human Gene Bank 
(Medical Genomics Research Center, KRIBB, Daejeon, Korea).
RNA isolation and reverse transcription-polymerase 
chain reaction
Total RNA was extracted from human gastric cancer cells and 
tissues obtained from patients using TRIzol reagent (Invitro-
gen) according to the manufacturer’s protocol. Reverse tran-
scription (RT) was carried out using a RT system (Toyobo, Osaka, 
Japan), and PCR was performed using Ex-Taq DNA Polymerase 
(Takara Bio Inc, Shiga, Japan). The primer sequences were as 
follows: HSF1, 5'-GACATAAAGATCCGCCAGGA-3' (sense) 
and 5'-CTGCACCAGTGAGATCAGGA-3' (antisense); β-actin: 
5'-AGCCTCGCCTTTGCCGA-3' (sense) and 5'-CTGGTGCCT 
GGGGCG-3' (antisense).
Western blot analysis
Western blot analysis was carried out as described previous-
ly.19 Briefly, AGS and MKN28 cells were lysed by radioimmu-
noprecipitation assay buffer (Biosesang Inc, Seongnam, Ko-
rea) containing a protease inhibitor cocktail and phosphatase 
inhibitor cocktail (GeneDEPOT, Barker, TX, USA), followed by 
sonication on ice. A total of 20 μg of protein was separated by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis 
and transferred onto a polyvinylidene fluoride membrane 
(Merck, Kenilworth, NJ, USA). After blocking with 5% skim 
milk for 1 hour, the membrane was incubated overnight with 
anti-HSF1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
primary antibody in 5% bovine serum albumin at 4°C. Anti-β-
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actin (Santa Cruz Biotechnology) was used as a control. The 
membrane was then incubated with a secondary antibody 
(goat-anti-rabbit IgG) for 90 min, followed by detection of 
protein bands with an enhanced chemiluminescence kit (Bio-
Rad, Hercules, CA, USA) using Supernova-Q1800.
Human gastric cancer tissue microarray analyses 
For immunohistochemical (IHC) analysis, core tissue biopsy 
specimens (2-mm diameter) were obtained from individual 
paraffin-embedded gastric carcinomas (donor blocks) and ar-
ranged in new recipient paraffin blocks (tissue array blocks) us-
ing a trephine apparatus (SuperBioChips Laboratories, Seoul, 
Korea). IHC analysis of HSF1 was performed as described 
previously.20 Immunohistochemistry of HSF1 revealed nuclear 
positivity and no cytoplasmic reaction in either normal muco-
sa cell or gastric cancer cells. The intensity of HSF1 staining 
was initially scored from 0 to 3 as follows: 0, no nuclear stain-
ing; 1, weak; 2, moderate; and 3, strong nuclear positivity. No 
gastric cancer samples were negative for HSF1 immunohisto-
chemistry. Then, gastric cancer samples were grouped into 
those with staining intensities of 1–2 (low expression) and 3 
(high expression) for statistical correlation and survival rate 
calculation.
Gene expression profiles using cDNA microarray data 
and analysis of public dataset
GSE13861, GSE13195, and GSE30727, as available datasets, 
were downloaded from the Gene Expression Omnibus (GEO) 
database (http://www.ncbi.nlm.nih.gov/geo/). GSE13861 was 
developed from 65 primary gastric adenocarcinomas, six gas-
trointestinal stromal tumors, and 19 surrounding normal fresh 
frozen tissues. GSE13195 and GSE30727 were developed, re-
spectively, from 25 pairs and 30 matching pairs of gastric cancer 
and normal surrounding tissue. These three datasets were nor-
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Fig. 1. Evaluation of the correlation between HSF1 expression and survival rate of patients with gastric cancer using public databases. (A-C) Expression lev-
els of HSF1 mRNA in tumor and normal tissues from the GEO database. Public datasets are presented as a scatter diagram: (A) GSE13861, (B) GSE13195, 
and (C) GSE30727. p values were calculated using Student’s t-test (A and B: *p<0.001; C, p=0.061). (D) Kaplan-Meier survival plots demonstrate the poor 
prognostic effect of HSF1 upregulation, which was correlated with worse overall survival, in patients with gastric cancer (probe 1: 202344_at, n=876; 
probe 2: 213756_s_at, n=876). HSF1, heat shock factor 1; HR, hazard ratio.
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malized using GEO2R, and a scatter plot for the expression 
pattern analysis was obtained.
Kaplan-Meier analysis of overall survival 
Kaplan-Meier analysis of overall survival for patients with gas-
tric cancer was performed using the online resource Kaplan-
Meier Plotter, as a public database (http://kmplot.com/analy-
sis).21 To investigate the prognostic value of HSF1, the patient 
cohorts were divided into two groups according to their medi-
an (or upper/lower quartile) expression of HSF1, and the da-
tabase was analyzed by a PostgreSQL server (https://www.
postgresql.org/about/servers/). The two patient cohorts were 
compared by a Kaplan-Meier survival plot, and hazard ratios 
with 95% confidence intervals and log rank p values were cal-
culated. 
Statistical analysis
Statistical analyses were performed using GraphPad Prism 5 
(GraphPad Software, Inc., San Diego, CA, USA). The data were 
analyzed by Student’s t-test and one-way ANOVA, unless oth-
erwise specified. Differences in patient survival were deter-
mined using the Kaplan-Meier method. Results are presented 
as a mean±SEM. Values of p<0.05 were considered statistically 
significant.
RESULTS
Analysis of HSF1 expression and survival rate using 
cDNA microarray data in gastric cancer patients
First, we aimed to identify relationships between high expres-
sion of HSF1 and poor survival in gastric cancer using the GEO 
database (Fig. 1A-C) and Kaplan-Meier analysis for gastric can-
cer patients (Fig. 1D). We collected three (GSE13861, GSE13195, 
and GSE30727) public datasets of patients with gastric cancer 
and compared the expression levels of HSF1 in tumor and 
normal gastric tissues (Fig. 1A-C). In all three datasets, the ex-
pression of HSF1 was higher in tumor tissue than in normal 
tissue. Expression was found to be statistically significant in 
two of the datasets (Fig. 1A and B; p<0.001). Fig. 1C depicts a 
trend in higher expression of HSF1 in tumor tissues than in 
normal tissues (p=0.061). Furthermore, statistical analysis of 
tumor tissue from the public database of patients with gastric 
cancer revealed a correlation between high expression of HSF1 
and a significantly lower probability of survival (Fig. 1D). 
HSF1 protein expression upregulated in patients with 
gastric cancer and correlated with poor survival 
To determine HSF1 protein expression levels in patients with 
gastric cancer, a tissue microarray (TMA) of 54 patients was 
prepared and IHC analysis was performed (Table 1 and Fig. 
2A). High expression of HSF1 was detected in tumor tissues 
from the patients with intestinal and diffuse types of gastric 
cancer, and most HSF1 expression was localized in the nucle-
us. HSF1 expression was notably upregulated in tumor tissues 
from patients with gastric cancer (Fig. 2A). Quantitative analy-
sis of HSF1 staining confirmed that patients with gastric cancer 
exhibited higher expression of HSF1 in tumor tissues than in 
normal tissues (Fig. 2B). As shown in Table 1, the expression 
levels of HSF1 were analyzed with respect to clinical factors. 
Based on the expression level of HSF1, gastric cancer tissues 
were further classified as high (score 3) and low (score 1 and 
2) groups. TMA results confirmed the absence of any signifi-
cant correlation between HSF1 expression and clinicopatho-
logical findings (Table 1). However, the expression of HSF1 
was significantly higher in tumor tissue than in the paired 
normal tissue in patients with gastric cancer (Fig. 2B). The 
probability of survival was significantly lower for patients with 
gastric cancer exhibiting high HSF1 expression levels in tumor 
tissues (Fig. 2C). These data strongly indicate that HSF1 expres-
sion is upregulated during the progression of gastric cancer.
Table 1. Correlation between HSF1 Expression and Clinicopathological 
Parameters in Gastric Cancer
Characteristic
HSF1 in tumor tissues
Low (n=35) High (n=19) p value*
Sex 0.533
Male 26 12
Female 9 7
Age (yr) 1
<60 16 8
≥60 19 11
Differentiation 0.935
Well 15 7
Moderately 9 5
Poorly 11 7
LN metastasis 0.134
Positive 19 15
Negative 16 4
Lauren’s classification 0.766
Intestinal 24 12
Diffuse 11 7
T classification 0.327
T1 12 4
T2 5 1
T3 11 11
T4 7 3
TNM stage 0.095
I 14 3
II 8 5
III 13 9
IV 0 2
*Fisher’s exact test was used to analyse the significance of the associations be-
tween Tumor groups and each characterisitcs.
HSF1, heat shock factor 1; LN, lymph node.
HSF1 high-expression (scored 3) and low-expression (scored 1 and 2) groups.
1045
Seok-Jun Kim, et al.
https://doi.org/10.3349/ymj.2018.59.9.1041
Knockdown of HSF1 reduces the proliferation, 
migration, and invasion of gastric cancer cells
We have previously confirmed the overexpression of HSF1 pro-
tein in gastric cancer cell lines.20 We examined the effects of 
loss- and gain-of-function of HSF1 in AGS and MKN28 cells by 
evaluating the mRNA and protein expressions of HSF1 (Fig. 
3A). The mRNA and protein expressions of HSF1 were knocked 
down with two specific siRNAs, and the efficiency of interfer-
ence was confirmed by RT-PCR and Western blot analysis 
(Fig. 3A). After the knockdown of HSF1, cell proliferation was 
analyzed by WST assay. As a result, we found that the knock-
down of HSF1 expression significantly reduced the prolifera-
tion of gastric cancer cells (Fig. 3B). Transwell migration and 
invasion assays showed that HSF1 knockdown inhibited the 
migration and invasion of gastric cancer cells (Fig. 3C and D). 
These results indicate that HSF1 induces the progression of 
gastric cancer.
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Fig. 2. High expression of HSF1 associated with poor survival in patients with gastric cancer. (A) In situ expression of HSF1 in normal and tumor tissues 
from patients with intestinal and diffuse types of gastric cancer was detected by immunohistochemistry and hematoxylin and eosin staining (magnifi-
cation: ×200). (B) Comparative analysis of HSF1 expression in normal and tumor tissues from patients with gastric cancer based on staining intensity. p 
values were calculated using Student’s t-test and significant differences are indicated by * (*p<0.001). (C) Kaplan-Meier analysis of survival curves for 
patients with gastric cancer according to the expression of HSF1 in tumor tissues (n=54). HSF1 high-expression group (score 3) had a much lower sur-
vival rate at 125 months than the HSF1 low-expression group (score 1 or 2). HSF1, heat shock factor 1.
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Overexpression of HSF1 induces proliferation, 
migration, and invasion of gastric cancer cells
The effects of the gain-of-function of HSF1 in AGS and MKN28 
gastric cancer cells were examined. The cells were transiently 
transfected with a HSF1 overexpression vector or empty vec-
tor for 48 hours. Overexpression of HSF1 was confirmed by 
RT-PCR and Western blot analysis (Fig. 4A). Overexpression of 
HSF1 significantly increased gastric cancer cell proliferation 
(Fig. 4B), migration (Fig. 4C), and invasion (Fig. 4D). These 
findings suggest that HSF1 participates in the progression of 
gastric cancer.
DISCUSSION
Our study demonstrated that the silencing of HSF1 expression 
results in a reduction in the proliferation, migration, and inva-
sion of gastric cancer cells, while HSF1 overexpression elicits 
the opposite effects on gastric cancer cells. Furthermore, the 
high expression of HSF1 was found to be correlated with poor 
prognosis in patients with gastric cancer. 
HSF1 regulates the expression of HSPs by binding to con-
sensus motifs, such the heat shock elements. HSPs are highly 
conserved stress proteins that are expressed and induced in 
response to heat shock or other stress factors or unfavorable 
conditions, such as inflammation, ischemia, infection, or car-
cinogenesis.12,22,23 In gastric cancer, HSP70 has been reported 
as a high-risk factor, and HSP90 inhibitor has been used for 
therapeutic purposes.24,25 We previously reported that HSF1 
regulates neogenin-1 expression to promote motility of gastric 
cancer cells by binding with galectin-3.20 These studies show 
that HSP and HSF1 contribute to the tumorigenesis or progres-
sion of gastric cancer. However, the role of HSF1 in gastric can-
cer has remained unclear.
The protein HSF1 was recently shown to play a significant 
role in the development and progression of a variety of can-
cers.9 In particular, HSF1 was described as playing an essential 
role in the development of lymphoma in p53-deficient mouse 
and carcinomas in a Ras tumor model.26,27 In hepatocellular 
carcinoma (HCC), HSF1 has been found to directly activate 
miR-135b expression and to promote HCC cell motility.28 Fur-
thermore, IHC analysis has revealed HSF1 as a prognostic mark-
er for breast cancer.15,29 High level expression of HSF1 was also 
reported in cervical, colon, lung, pancreatic, osteosarcoma, 
and prostate cancers.16,18,30,31 These studies suggest that HSF1 
may serve as a key regulator of tumorigenesis in a variety of 
cancers, including breast cancer.
Using three sets of GEO datasets, our study confirmed in-
creased levels of HSF1 mRNA expression in tumor tissues 
from patients with gastric cancer. Furthermore, the high level 
of HSF1 expression was correlated with poor overall survival. 
We confirmed the protein expression level of HSF1 in 54 tu-
mor samples from patients with gastric cancer and found that 
the expression level of HSF1 protein was consistent with the ex-
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Fig. 3. Downregulation of HSF1 expression reduces proliferation, migration, and invasion of gastric cancer cells. AGS and MKN28 cells were trans-
fected with a scrambled siRNA (scRNA) or two small-interfering RNAs (siRNAs) specific for HSF1 (siRNA #1 and #2). (A) HSF1 protein expression was 
detected by Western blot analysis. β-actin was used as a loading control. (B) WST assay was performed to detect cell viability. (C and D) Transwell assays 
to evaluate (C) migration and (D) invasion of cells (×200). The histogram is represented as mean±SEM (n=3). p values were calculated using ANOVA and 
statistically significant differences are indicated as * (*p<0.001). HSF1, heat shock factor 1.
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pression levels of HSF1 mRNA. 
Although we observed no significant correlation between 
HSF1 expression and clinicopathological findings, HSF1 ex-
pression was increased in tumor tissues and was correlated 
with poor overall survival. To determine whether HSF1 expres-
sion is important for tumor growth and cell motility, we per-
formed loss-of-function and gain-of-function analyses in gas-
tric cancer cells. Downregulation of HSF1 significantly delayed 
the growth and motility of gastric cancer cells, while the over-
expression of HSF1 increased cell growth and motility. Fur-
ther studies evaluating the role of HSF1 in gastric cancer using 
large scale clinical data are warranted.
In conclusion, the present study demonstrated increases in 
the expression levels of HSF1 in gastric cancer tissues, com-
pared to paired normal tissue. We deemed that HSF1 promotes 
the proliferation, migration, and invasion of gastric cancer cells 
and confirmed that HSF1 expression is correlated with poor 
prognosis in patients with gastric cancer. Thus, our study doc-
uments the essential role of HSF1 in gastric cancer progression, 
suggesting its potential role as a prognostic maker for gastric 
cancer.
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